| [1] |
中国高血压防治指南修订委员会，高血压联盟(中国医疗保健国际交流促进会高血压病学分会,等.中国高血压防治指南(2024年修订版)全文替换[J].中华高血压杂志,2024,32(7):603-700.
|
| [2] |
中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会, 等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志, 2018, 46(9):680-694.
|
| [3] |
中华医学会心血管病学分会 中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
|
| [4] |
Hypertension control. Report of a WHO expert committee[J]. World Health Organ Tech Rep Ser, 1996, 862:1-83.
|
| [5] |
Wang JG. Chinese Hypertension Guidelines[J]. Pulse (Basel), 2015, 3(1):14-20.
|
| [6] |
Krzesinski JM. New American and European 2003 guidelines for the management of arterial hypertension[J]. Rev Med Liege, 2003, 58(9):563-571.
|
| [7] |
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis[J]. Lancet, 2005, 366(9496):1545-1553.
|
| [8] |
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023, 41(12):1874-2071.
|
| [9] |
McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension[J]. Eur Heart J, 2024, 45(38):3912-4018.
|
| [10] |
Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials[J]. BMJ, 2003, 326(7404):1427.
|
| [11] |
Guo QH, Zhu ZM, Feng YQ, et al. Blood pressure lowering effects of β-blockers as add-on or combination therapy: a meta-analysis of randomized controlled trials[J]. J Clin Hypertens (Greenwich), 2023, 25(3):227-237.
|
| [12] |
Mancia G, Brunström M, Burnier M, et al. Rationale for the inclusion of β-blockers among major antihypertensive drugs in the 2023 European Society of Hypertension guidelines[J]. Hypertension, 2024, 81(5):1021-1030.
|
| [13] |
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177.
|
| [14] |
应用β肾上腺素能受体阻滞剂规范治疗冠心病中国专家共识组. 应用β肾上腺素能受体阻滞剂规范治疗冠心病的中国专家共识[J]. 中国循环杂志, 2020, 35(2):108-123.
|
| [15] |
Hu MJ, Wang XN, Tan JS, et al. Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: an updated systematic review and meta-analysis[J]. Arch Cardiovasc Dis, 2022, 115(12):637-646.
|
| [16] |
Xu S, Li Z, Yang T, et al. Association between early oral β-blocker therapy and risk for in-hospital major bleeding after percutaneous coronary intervention for acute coronary syndrome: findings from CCC-ACS project[J]. Eur Heart J Qual Care Clin Outcomes, 2022 :qcac036.
|
| [17] |
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720-3826.
|
| [18] |
中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 非ST段抬高型急性冠脉综合征诊断和治疗指南(2024)[J]. 中华心血管病杂志, 2024, 52(6):615-646.
|
| [19] |
Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3):407-477.
|
| [20] |
Khorsandi M, Blumenthal RS, Blaha MJ, et al. The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease[J]. Clin Cardiol, 2024, 47(5):e24284.
|
| [21] |
Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes[J]. Eur Heart J, 2024, 45(36):3415-3537.
|
| [22] |
Puymirat E, Riant E, Aissaoui N, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study[J]. BMJ, 2016, 354:i4801.
|
| [23] |
Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study[J]. Eur Heart J, 2020, 41(37):3521-3529.
|
| [24] |
Joo SJ, Kim SY, Choi JH, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction[J]. Eur Heart J Cardiovasc Pharmacother, 2021, 7(6):475-482.
|
| [25] |
Holt A, Blanche P, Zareini B, et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study[J]. Eur Heart J, 2021, 42(9):907-914.
|
| [26] |
Ishak D, Aktaa S, Lindhagen L, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes[J]. Heart, 2023, 109(15):1159-1165.
|
| [27] |
Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction[J]. N Engl J Med, 2024, 390(15):1372-1381.
|
| [28] |
Silvain J, Cayla G, Ferrari E, et al. Beta-blocker interruption or continuation after myocardial infarction[J]. N Engl J Med, 2024, 391(14):1277-1286.
|
| [29] |
中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3):235-275.
|
| [30] |
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. PLoS Med, 2009, 6(7):e1000097.
|
| [31] |
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27):2129-2200.
|
| [32] |
Arnold SV, Silverman DN, Gosch K, et al. Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction[J]. JACC Heart Fail, 2023, 11(8 Pt 1):893-900.
|
| [33] |
Ibrahim J, Fabrizio C, Sezer A, et al. Beta blockers are associated with lower all-cause mortality among HFpEF patients[J]. Clin Res Cardiol, 2024, 113(6):951-958.
|
| [34] |
Kaddoura R, Madurasinghe V, Chapra A, et al. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis[J]. Curr Probl Cardiol, 2024, 49(3):102376.
|
| [35] |
van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure)[J]. J Am Coll Cardiol, 2009, 53(23):2150-2158.
|
| [36] |
Mulder BA, van Veldhuisen DJ, Crijns HJ, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS[J]. Eur J Heart Fail, 2012, 14(10):1171-1178.
|
| [37] |
Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis[J]. Lancet, 2014, 384(9961):2235-2243.
|
| [38] |
Cleland J, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J, 2018, 39(1):26-35.
|
| [39] |
中华医学会心血管病学分会，中国生物医学工程学会心律分会. 抗心律失常药物临床应用中国专家共识[J]. 中华心血管病杂志, 2023, 51(3):256-269.
|
| [40] |
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2024, 149(1):e1-e156.
|
| [41] |
吴寸草，郭继鸿. 长QT综合征: β受体阻滞剂种类的选择与靶剂量[J/OL]. 中华心脏与心律电子杂志, 2014, 2(2):50-52.
|
| [42] |
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2018, 72(14):e91-e220.
|
| [43] |
赵婕，刘学军. β受体阻滞剂治疗COPD合并心血管疾病的研究进展[J]. 中西医结合心脑血管病杂志, 2022, 20(8):1442-1444.
|
| [44] |
Short PM, Lipworth SI, Elder DH, et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study[J]. BMJ, 2011, 342:d2549.
|
| [45] |
Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with a reduction in COPD exacerbations[J]. Thorax, 2016, 71(1):8-14.
|
| [46] |
Mirza S, Clay RD, Koslow MA, et al. COPD guidelines: a review of the 2018 GOLD report[J]. Mayo Clin Proc, 2018, 93(10):1488-1502.
|
| [47] |
Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD[J]. N Engl J Med, 2019, 381(24):2304-2314.
|
| [48] |
Devereux G, Cotton S, Nath M, et al. Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS randomized clinical trial[J]. JAMA, 2024, 332(6):462-470.
|